21:57 , Feb 14, 2019 |  BC Innovations  |  Emerging Company Profile

Indalo: Integral to fibrosis

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo President and CEO Robert...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Financial News

Euclises financial update

Euclises Pharmaceuticals Inc. , St. Louis, Mo.   Business: Cancer   Date announced: 2015-04-07   Note: Euclises raised $601,000 in a second close of a series A round, bringing the total raised in the round...
08:00 , Feb 16, 2015 |  BioCentury  |  Emerging Company Profile

COX-ing cancer into submission

Euclises Pharmaceuticals Inc. is developing two COX-2 inhibitor programs, one via a prodrug approach and one using deuteration, which are designed to minimize the gastrointestinal side effects that curtailed development of first-generation inhibitors for cancer....
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Euclises completes venture financing

Euclises Pharmaceuticals Inc. , St. Louis, Mo.   Business: Cancer, Inflammation   Date completed: 2014-09-09   Type: Venture financing   Raised: $1.3 million   Investors: Cultivation Capital; BioGenerator; Missouri Technology Corp.; Analytical Bio-Chemistry Laboratories Inc.;...
07:00 , Sep 16, 2013 |  BioCentury  |  Emerging Company Profile

Tansna: Quieting convulsions

Propofol is used off-label in hospitals to treat uncontrolled seizures, but its potent sedative properties preclude everyday use. Tansna Therapeutics Inc. is developing non-sedating analogs of propofol that could help treat the one-third of epilepsy...
08:00 , Nov 19, 2012 |  BioCentury  |  Emerging Company Profile

Confluence: KINecting discovery

Confluence Life Sciences Inc. is building a library of chemical probes that interact with cysteine-containing active sites of certain kinases, which could allow for quicker and more efficient discovery of inhibitors of difficult targets. A...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Financial News

Confluence Life Sciences completes venture financing

Confluence Life Sciences Inc. , St. Louis, Mo.   Business: Cancer, Inflammation   Date completed: 9/17/12   Type: Venture financing   Raised: $4 million   Investors: DFJ Mercury; BioGenerator; Missouri Technology; Helix Fund  ...
07:00 , Sep 19, 2011 |  BioCentury  |  Emerging Company Profile

Galera: Replacing SOD

Galera: Replacing SOD Galera Therapeutics LLC believes its small molecule that mimics the activity of superoxide dismutase can help kill cancer cells while simultaneously preventing side effects of chemoradiation. The company plans to start a...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Financial News

Mobius Therapeutics completes venture financing

Mobius Therapeutics LLC , St. Louis, Mo.   Business: Ophthalmic   Date completed: 2/4/11   Type: Venture financing   Raised: $150,000   Investor: BioGenerator  ...